Welcome to our dedicated page for Intelligent Bio Solutions news (Ticker: INBS), a resource for investors and traders seeking the latest updates and insights on Intelligent Bio Solutions stock.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company focused on intelligent, rapid, non-invasive testing solutions, with a primary emphasis on its Intelligent Fingerprinting Drug Screening System. The INBS news feed on Stock Titan aggregates company announcements, press releases and related coverage so readers can follow developments around its fingerprint-based drug screening platform, partnerships and capital markets activity.
Recent news highlights include record fiscal 2026 first quarter revenue driven by consumable cartridge sales, the addition of dozens of new customer accounts across more than 24 countries, and large deployments with organizations in sectors such as industrial services and public transport. Updates also cover the company’s razor–razor-blade business model, where installed readers support recurring cartridge revenue, and its efforts to expand adoption in safety-critical industries like construction, manufacturing and engineering, transport and logistics, mining and government administration.
INBS news items frequently address strategic partnerships and manufacturing, such as the collaboration with Syrma Johari MedTech Ltd to scale production of the Intelligent Fingerprinting Drug Screening Reader, and the alliance with Vlepis Pty Ltd to explore wearable patch technologies and consumer health monitoring. Additional coverage includes the distribution agreement for the SmarTest Patch, a 7–10 day continuous drug monitoring solution, and updates on regulatory pathways, including anticipated FDA 510(k) submissions.
Investors can also track capital structure and listing-related developments, including reverse stock split decisions, Nasdaq bid price deficiency notices and private placement financings with institutional investors. By reviewing the INBS news stream, readers gain context on how Intelligent Bio Solutions is executing its commercial strategy, expanding its customer base, managing manufacturing partnerships and addressing regulatory and listing requirements over time. Bookmark this page to quickly access the latest official communications and market-moving updates related to INBS.
Intelligent Bio Solutions (INBS) announces a new partnership with Avon Freight Group, implementing its fingerprint drug testing solution across three UK sites. This marks Avon's first in-house drug testing program, replacing their previous external oral swab testing method. INBS has expanded its presence to over 400 accounts across 19 countries.
The partnership highlights INBS's growth in the UK drug testing market, which is projected to reach $453 million by 2030. The company's non-invasive, rapid testing solution offers a more efficient and respectful alternative to traditional methods. Following its FDA 510(k) submission in December 2024, INBS is preparing for U.S. market expansion in 2025, positioning itself as a scalable, cost-effective leader in the drug testing industry.
Intelligent Bio Solutions (INBS) has announced preliminary unaudited financial results for fiscal Q2 and six months ended December 31, 2024. The company reported unaudited revenue of $0.61 million for Q2 and $1.48 million for the six-month period. Gross profit is expected to increase by 32.6% from $0.43 million to $0.57 million, with gross profit margin expanding to 38.5% from 27.7%.
The improved profitability is primarily driven by increased sales of high-margin cartridges used in the Intelligent Fingerprinting Drug Screening System. The company's total calendar year revenue grew 23% year-on-year, supported by a base of over 400 accounts. During Q2, INBS submitted a 510(k) premarket notification to the FDA for its drug screening system and formed strategic partnerships to expand its presence in the U.S. and international markets.
Intelligent Bio Solutions (INBS) announced a major upgrade to its Intelligent Fingerprinting Drug Screening System, introducing multilingual capabilities that will make the system accessible to over 4 billion users worldwide. The upgrade will support multiple languages across North and South America, Europe, Asia Pacific, and the Middle East.
The enhancement aims to improve usability in safety-critical industries such as construction, mining, manufacturing, transport, and logistics. This development aligns with the company's global expansion strategy, including its planned entry into the US market in 2025, following its FDA 510(k) submission in December 2024.
The company's non-invasive drug testing solution uses fingerprint sweat analysis to detect multiple substances simultaneously. INBS currently maintains presence in 19 countries, targeting the workplace drug testing market, which is projected to reach approximately $8 billion globally by 2030.
Intelligent Bio Solutions (INBS) announced that Quantum Traffic Management, a UK-based traffic management provider, has implemented INBS' Intelligent Fingerprinting Drug Testing Solution across its 10 nationwide sites. This transition from traditional saliva and urine testing to fingerprint sweat-based drug screening aims to enhance workplace testing efficiency and safety.
Quantum TM joins INBS's portfolio of more than 400 accounts across 19 countries. The fingerprint sweat-based system enables on-site drug screening without specialized staff or facilities, providing rapid results and improved operational efficiency. The company submitted an FDA 510(k) application in December 2024 and plans to enter the US market in 2025.
Intelligent Bio Solutions (INBS) has strengthened its presence in Europe and the Middle East through a partnership with IVY Diagnostics. The collaboration aims to expand the adoption of INBS' Intelligent Fingerprinting Drug Testing Solution, focusing on drug rehabilitation and law enforcement applications.
IVY Diagnostics has secured a tender in Italy to provide INBS' drug screening technology for rehabilitation programs. The solution is also undergoing trials with Turin's local police force for roadside screening. The European drug screening market is projected to reach $3.6 billion by 2030, while the Middle East and Africa market is expected to reach $432.7 million.
IVY Diagnostics serves as INBS' primary European contact, helping expand into Romania, Hungary, Slovakia, Austria, Scandinavia, UAE, Saudi Arabia, and Qatar through its distributor network.
Intelligent Bio Solutions (INBS) announced that Princebuild, a UK construction firm with seven sites, has adopted INBS' Intelligent Fingerprinting Drug Screening System, transitioning from saliva testing to fingerprint drug screening. The system offers a more streamlined, in-house solution prioritizing efficiency, accuracy, and employee privacy.
Princebuild joins INBS' portfolio of over 400 accounts across 19 countries, including notable construction companies like Mount Anvil, Hayfield Homes, Stonbury, MBP Structures, and PJ Hegarty & Sons U.K. The technology is used across multiple industries, including construction, mining, manufacturing, transport, law enforcement, and forensics.
Following its FDA 510(k) submission in December 2024, INBS plans to enter the US market in the first half of 2025, targeting expansion in the drug screening products market.
Intelligent Bio Solutions (INBS) has submitted a 510(k) premarket notification to the FDA for its Intelligent Fingerprinting Drug Screening System, a non-invasive drug testing solution. The system demonstrated 94.1% accuracy in performance studies and showed fingerprint sweat provides reliable drug detection comparable to blood tests at 95% confidence level.
The technology delivers results within 10 minutes through sweat collected from fingertips, targeting safety-critical industries like construction, mining, and transportation, as well as law enforcement and drug rehabilitation sectors. INBS aims to enter the US market in 2025, expanding its presence beyond existing international markets where the system has already proven cost-effective and operationally efficient.
Intelligent Bio Solutions (INBS) has announced a virtual fireside chat scheduled for December 11, 2024, at 4:30 p.m. ET. The event will feature President & CEO Harry Simeonidis and CFO Spiro Sakiris, who will discuss the company's recent clinical study results and their path to FDA 510(k) submission.
The virtual presentation will include a Q&A session for investors, and a recording will be made available on the company's Investor Relations website following the event. Interested participants can register through the provided Zoom webinar link.
Intelligent Bio Solutions (INBS) has successfully completed its method comparison study for the Intelligent Fingerprinting Drug Screening System, achieving 94.1% accuracy, 82.2% sensitivity, and 100% specificity. The study, conducted with CenExel using 135 healthy donors and nine system operators, compared fingerprint sweat opiate screening tests with laboratory LC-MS/MS methods. This milestone, along with recent positive Pharmacokinetic study results, supports INBS's planned FDA 510(k) submission in Q4 2024. If approved, the company aims to launch its non-invasive drug screening technology in the US market in 2025.
Intelligent Bio Solutions (Nasdaq: INBS), a medical technology company focused on rapid, non-invasive testing solutions, has announced its participation in the Noble Capital Markets' 20th Annual Emerging Growth Equity Conference. The event will take place on December 3-4, 2024, at Florida Atlantic University in Boca Raton, FL.
The company's management team is scheduled to present on Wednesday, December 4, 2024, at 2:00 p.m. ET in Presentation Room 3. A recording of the presentation will be available on INBS's Investor Relations website two days after the event. The management team will also be available for one-on-one meetings with investors during the conference.